Related Experiment Videos
Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1a
Abstract:
The effect of recombinant human interleukin-1a on the survival rate of Std-ddY male mice systemically infected with Pseudomonas aeruginosa 12 or Klebsiella pneumoniae P-5709 was evaluated. In P. aeruginosa infection, interleukin-1a given intramuscularly twice, 3 days and 1 day before inoculation of bacteria, most effectively protected animals from death due to infection. The effect was dose dependent, with a maximum survival rate of 92.5% at 10 micrograms per mouse, while only 8.3% of the control group survived until the end of the observation period. The 50% effective dose of interleukin-1a was 0.261 microgram per mouse. In K. pneumoniae infection, interleukin-1a given intramuscularly twice, simultaneously with and 1 day after the inoculation of bacteria, was most effective. The protective effect of interleukin-1a was again dose dependent and was generally more marked than in P. aeruginosa infection. The 50% effective dose was 0.034 microgram per mouse. In both infections, there was no significant increase in the survival rates of animals injected with human albumin or heat-inactivated interleukin-1a. These observations raise the possibility that human interleukin-1a could serve as a therapeutic tool for patients with bacterial infections.
Insights
Recombinant human interleukin-1 alpha (IL-1α) significantly enhanced survival rates in mice infected with Pseudomonas aeruginosa and Klebsiella pneumoniae. This cytokine shows potential as a therapeutic agent for bacterial infections.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Bacterial infections pose a significant global health threat.
- Interleukin-1 alpha (IL-1α) is a key inflammatory cytokine with known immunomodulatory functions.
Purpose of the Study:
- To evaluate the efficacy of recombinant human interleukin-1 alpha (IL-1α) in improving survival rates of mice challenged with Pseudomonas aeruginosa and Klebsiella pneumoniae.
- To determine the dose-dependency and optimal administration timing of IL-1α in combating these bacterial infections.
Main Methods:
- Std-ddY male mice were systemically infected with P. aeruginosa or K. pneumoniae.
- Recombinant human IL-1α was administered intramuscularly at varying doses and time points relative to bacterial inoculation.
- Survival rates of treated mice were compared to control groups receiving human albumin or heat-inactivated IL-1α.
Main Results:
- IL-1α significantly increased survival in both P. aeruginosa and K. pneumoniae infections in a dose-dependent manner.
- Optimal protection against P. aeruginosa was achieved with IL-1α administration 3 days and 1 day before infection (92.5% survival at 10 µg/mouse).
- For K. pneumoniae, IL-1α was most effective when given simultaneously with and 1 day after infection (ED50 = 0.034 µg/mouse).
- No survival benefit was observed with human albumin or heat-inactivated IL-1α, confirming the specificity of the effect.
Conclusions:
- Recombinant human IL-1α demonstrates potent therapeutic potential against severe bacterial infections caused by P. aeruginosa and K. pneumoniae.
- The timing and dosage of IL-1α administration are critical for maximizing its protective effects.
- These findings suggest that human IL-1α could be developed as a novel therapeutic strategy for bacterial infections.